These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32685037)

  • 21. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
    Wiesli P; Schories M
    Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of insulin glargine Gla-300 in insulin-naïve type 2 diabetes subjects in a real-life setting-the GOAL_RO trial.
    Stegaru D; Nicodim S; Vladu D; Guțu O; Onaca A; Pîrvu F; Moise M; Guja C
    Ann Transl Med; 2021 Jan; 9(2):105. PubMed ID: 33569407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Where to Initiate Basal Insulin Therapy: Inpatient or Outpatient Department? Real-World Observation in China.
    Chen M; Zhang P; Zhao Y; Duolikun N; Ji L
    Diabetes Metab Syndr Obes; 2022; 15():3375-3385. PubMed ID: 36341227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study.
    Velojic-Golubovic M; Ciric V; Dimitrijevic M; Kovic T; Mitic M; Olujic B; Pevac N; Radenkovic S; Radojkovic D; Vukadinovic S; Popovic DS
    Diabetes Ther; 2021 Jul; 12(7):2049-2058. PubMed ID: 34160790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA; Zhou S; Gill J; Wei W
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and safety of basal insulin therapy in type 2 diabetes mellitus patients with or without metformin observed in a national cohort in China.
    Zhang P; Chen M; Zhang H; Luo Y; Zhu D; Li X; Ji J; Wang D; Duolikun N; Ji L
    BMC Endocr Disord; 2022 Jan; 22(1):26. PubMed ID: 35045841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
    Meneghini LF; Sullivan SD; Oster G; Busch R; Cali AMG; Dauchy A; Gill J; Bailey TS
    Diabetes Obes Metab; 2020 Nov; 22(11):2004-2012. PubMed ID: 32729217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.
    Blonde L; Meneghini L; Peng XV; Boss A; Rhee K; Shaunik A; Kumar S; Balodi S; Brulle-Wohlhueter C; McCrimmon RJ
    Diabetes Ther; 2018 Jun; 9(3):1347-1358. PubMed ID: 29600507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study.
    Gourdy P; Bahloul A; Boultif Z; Gouet D; Guerci B
    Diabetes Ther; 2020 Jan; 11(1):147-159. PubMed ID: 31782050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
    Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
    JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin Management of Patients with Inadequately Controlled Type 2 Diabetes Admitted to Hospital: Titration Patterns and Frequency of Hypoglycemia as Results of a Prospective Observational Study (Hospital Study).
    Brož J; Janíčková Žďárská D; Urbanová J; Piťhová P; Doničová V; Pálová S; Pelechová B; Smržová A; Kvapil M
    Diabetes Ther; 2021 Jul; 12(7):1799-1808. PubMed ID: 34028699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China.
    Ji L; Zhang P; Zhu D; Li X; Ji J; Lu J; Guo X; Jia W; Weng J; Wu Y; Yang W; Zou D; Zhou Z; Pan C; Gao Y; Garg SK
    Diabetes Obes Metab; 2017 Jun; 19(6):822-830. PubMed ID: 28105735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study.
    Kesavadev J; Joshi SR
    J Assoc Physicians India; 2013 Jan; 61(1 Suppl):28-30. PubMed ID: 24482985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus.
    Pfützner A; Hermanns N; Funke K; Forst T; Behnke T; Bitton G; Nagar R; Raz I; Haak T
    Curr Med Res Opin; 2014 May; 30(5):753-60. PubMed ID: 24392996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individualized HbA
    Lautsch D; Boggs R; Wang T; Gonzalez C; Milligan G; Rajpathak S; Malkani S; McLeod E; Carroll J; Higgins V
    Adv Ther; 2022 Feb; 39(2):1016-1032. PubMed ID: 34951678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
    J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets.
    Dalal MR; Grabner M; Bonine N; Stephenson JJ; DiGenio A; Bieszk N
    Diabetes Res Clin Pract; 2016 Nov; 121():17-26. PubMed ID: 27616634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in HbA1c, insulin dose and incidence of hypoglycemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting: an observational study.
    Landstedt-Hallin L
    Curr Med Res Opin; 2015 Aug; 31(8):1487-93. PubMed ID: 26046236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study.
    Fadini GP; Buzzetti R; Fittipaldi MR; D'Incau F; Da Porto A; Girelli A; Simoni L; Lastoria G; Consoli A;
    Diabetes Ther; 2022 Aug; 13(8):1483-1497. PubMed ID: 35717487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.